Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.
- EligibilityCriteria: Inclusion Criteria:  Inclusion criteria for NIPP treatment  Age ≥ 18 years mRNA or DNA-based virus detection by smear (also external findings) Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 Written informed consent to participate in the study  Inclusion criteria for control group  Age ≥ 18 years Swab-based mRNA or DNA-based virus detection (also external findings) Clearly visible transformation zone of the cervix corresponding to T1/T2 Written informed consent to participate in the study  Exclusion criteria:  The following exclusion criteria apply to both groups of patients (NIPP treatment and control group).  Transformation zone not fully visible Evidence of invasive disease Serious cardiovascular diseases - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study includes patients aged 18 and over from the dysplasia clinic of the University Women's Hospital Tübingen who have been diagnosed with an infection of the cervix uteri involving both high- and low-risk HPV viruses. - SamplingMethod: Probability Sample